Angiotensin-Receptor Blockers Aren't Associated with Adverse Cardiovascular Outcomes
Published 2011 · P. Mueller, Facp.
NEJM Journal Watch
0
Citations
0
Influential Citations
Abstract
In 2004, a randomized trial suggested that valsartan (Diovan), an angiotensin-receptor blocker (ARB), was associated with excess risk for myocardial infarction (MI; JW Gen Med Jul 13 2004). In this systematic review and meta-analysis, investigators assessed whether risks for adverse …
Study Snapshot
Key takeawayAngiotensin-receptor blockers (ARBs) are not associated with increased risk of adverse cardiovascular outcomes, such as myocardial infarction, despite earlier reports.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.